Ironwood Pharmaceuticals | IRWD - Current Liabilities


Ironwood Pharmaceuticals reported $34.73M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Akebia Therapeutics USD 162.35M 1.48M Sep/2026
Almirall EUR 323.65M 26.99M Jun/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amarin USD 175.14M 10.94M Sep/2026
Ardelyx USD 127.8M 4.42M Sep/2026
Astellas Pharma JPY 1.1T 134.96B Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
Charles River Laboratories USD 1.09B 45.49M Sep/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Ironwood Pharmaceuticals USD 34.73M 1.88M Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
MacroGenics USD 107.23M 1.58M Sep/2026
Moderna USD 2.03B 506M Sep/2026
Myriad Genetics USD 130.7M 500K Jun/2026
Pacira USD 126.1M 4.08M Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Takeda JPY 2.6T 161B Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025